Connect Biopharma Holdings Limited CNTB · NASDAQ
$0.91 +0.01% (+$0.00)
Summary
30 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $27.0M against $596.0K.
- Analysts expect revenue to grow by 11,608% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
For the next fiscal year analysts expect revenue to grow by 11,608%.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 7
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $6.6 is 628% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- License 100%
By region
The company reports no revenue by region.
License brings in 100% of revenue.
Segments in detail